Ligand-targeted liposomal anticancer drugs

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Targeted delivery of anticancer drugs can improve therapeutic efficacy and reduce side effects.
• Liposomes are versatile nanocarriers for drug delivery.
• Selective targeting of tumor cells is crucial for effective cancer therapy.

Purpose of the Study:

• To review recent advances in ligand-targeted liposomes (LTLs) for anticancer drug delivery.
• To discuss new approaches in LTL design and optimization.
• To describe the advantages and potential challenges of LTL therapeutic applications.

Main Methods:

• Literature review of recent studies on ligand-targeted liposomes.
• Analysis of new technologies for ligand selection and LTL optimization.
• Discussion of therapeutic applications, advantages, and limitations of LTLs.

Main Results:

• Ligand-mediated targeting of liposomes to tumor antigens enhances drug delivery.
• New technologies expand ligand choices for improved targeting affinity, internalization, and size.
• LTLs show promise for increasing the therapeutic index of anticancer drugs.

Conclusions:

• Ligand-targeted liposomes represent a promising strategy for improving anticancer drug delivery.
• Ongoing technological advancements are facilitating the development and optimization of LTLs.
• Clinical translation of anticancer drugs encapsulated in LTLs is anticipated in the near future.